These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11642004)

  • 1. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics.
    Gras J; Llupià J; Llenas J; Palacios JM
    Arzneimittelforschung; 2001 Sep; 51(9):726-32. PubMed ID: 11642004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine.
    Gras J; Cardelús I; Llenas J; Palacios JM
    Eur J Pharmacol; 2000 Dec; 410(1):53-9. PubMed ID: 11134656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Almotriptan, a new anti-migraine agent: a review.
    Gras J; Llenas J; Jansat JM; Jáuregui J; Cabarrocas X; Palacios JM
    CNS Drug Rev; 2002; 8(3):217-34. PubMed ID: 12353056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.
    Bou J; Domènech T; Puig J; Heredia A; Gras J; Fernández-Forner D; Beleta J; Palacios JM
    Eur J Pharmacol; 2000 Dec; 410(1):33-41. PubMed ID: 11134654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional profile of almotriptan in animal models predictive of antimigraine activity.
    Gras J; Bou J; Llenas J; Fernández AG; Palacios JM
    Eur J Pharmacol; 2000 Dec; 410(1):43-51. PubMed ID: 11134655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profile and practice experience of almotriptan.
    Gendolla A
    Cephalalgia; 2004; 24 Suppl 2():16-23. PubMed ID: 15595990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Almotriptan: an effective and well-tolerated treatment for migraine pain.
    Pascual J
    Drugs Today (Barc); 2003; 39 Suppl D():31-6. PubMed ID: 15071618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study.
    Cabarrocas X; Esbri R; Peris F; Ferrer P
    Headache; 2001 Jan; 41(1):57-62. PubMed ID: 11168604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability.
    Von S
    Am J Manag Care; 2002 Feb; 8(3 Suppl):S74-9. PubMed ID: 11859907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers.
    Fleishaker JC; Sisson TA; Carel BJ; Azie NE
    Clin Pharmacol Ther; 2000 May; 67(5):498-503. PubMed ID: 10824628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
    John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
    J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
    Mannix LK; Adelman JU; Goldfarb SD; Von S; Kozma CM
    Am J Manag Care; 2002 Feb; 8(3 Suppl):S94-101. PubMed ID: 11859910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
    Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
    Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.
    Fleishaker JC; Ryan KK; Jansat JM; Carel BJ; Bell DJ; Burke MT; Azie NE
    Br J Clin Pharmacol; 2001 May; 51(5):437-41. PubMed ID: 11422001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
    Diener HC; Gendolla A; Gebert I; Beneke M
    Headache; 2005; 45(7):874-82. PubMed ID: 15985104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health outcomes evaluations: estimating the impact of almotriptan in managed care settings.
    Mayo KW; Osterhaus JT
    Am J Manag Care; 2002 Feb; 8(3 Suppl):S85-93. PubMed ID: 11859909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
    Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
    J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.